Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Invo Fertility Inc's Business Segments
Invo Fertility Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
2
Largest Segment
Fertility Clinic Services
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Fertility Clinic Services99.7%
- Invocell Device0.4%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Fertility Clinic Services | $ 2 | 99.7% |
| Invocell Device | $ 0 | 0.4% |
Revenue by Product & Service Category - Q2 FY2026
- Revenue From External Customers100%
- Clinic Revenue99.7%
- Product0.4%
- Inter Segment Revenue0.1%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Revenue From External Customers | $ 2 | 100% |
| Clinic Revenue | $ 2 | 99.7% |
| Product | $ 0 | 0.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Invo Fertility Inc dataset.
Description of Invo Fertility Inc
INVO Fertility, Inc. is a healthcare services and technology company specializing in the fertility market, primarily in the United States. The company’s main commercial strategy involves acquiring, establishing, and operating fertility clinics and related businesses and technologies. INVO Fertility operates four fertility clinics in the U.S. and sells and distributes its proprietary INVOcell® medical device to third-party fertility clinics. The company’s clinics provide fertility services including in vitro fertilization (IVF) and intravaginal culture (IVC) procedures enabled by the INVOcell device. INVO Fertility seeks to license or acquire additional fertility-focused technologies for use within its clinics. Recent acquisitions include the Wisconsin Fertility Institute and Family Beginnings, an Indiana-based fertility clinic. The acquisition of the Wisconsin Fertility Institute notably increased the company’s revenue and shifted its focus from a medical device company to a healthcare services company. INVO Fertility has also formed joint ventures to open INVO Centers in Alabama and Georgia to promote the INVOcell device and expand clinical data supporting the IVC procedure. The INVOcell device facilitates fertilization and early embryo development within the woman’s body, providing a cost-effective alternative to traditional IVF with comparable success rates.
The registrant operates through three reportable business segments: Clinic Services, INVOcell Device, and Therapeutics. The Clinic Services segment comprises financial information for WFI and the Atlanta Clinic. The INVOcell Device segment involves the manufacture and sales of the INVOcell device. The Therapeutics segment pertains to the subsidiary NTI, which was 80.1% divested during the second quarter of 2025; therefore, this segment includes NTI's results only through June 2, 2025. All operations and sales occur within the United States. Segment financials for 2025 and 2024 include revenues, costs, expenses, impairments, depreciation, and segment profits or losses, with reconciliations to income before taxes. No single customer accounted for 10% or more of consolidated revenues or trade accounts receivable in 2025 or 2024.